Literature DB >> 23985001

Diagnosis and treatment of hereditary hemochromatosis: an update.

Pushpjeet Kanwar1, Kris V Kowdley.   

Abstract

Hereditary hemochromatosis is an inherited iron overload disorder caused by inappropriately low hepcidin secretion leading to increased duodenal absorption of dietary iron, most commonly in C282Y homozygous individuals. This can result in elevated serum ferritin, iron deposition in various organs and ultimately end-organ damage, although there is incomplete biochemical and clinical penetrance and variable phenotypic expression of the HFE mutation in hereditary hemochromatosis. An elevated SF >1000 mg/l [corrected] is associated with an increased risk of cirrhosis and mortality in C282Y homozygotes.Conversely, a SF <1000 µg/l is associated with a very low likelihood of cirrhosis, making liver biopsy unnecessary among C282Y homozygotes in the absence of concomitant risk factors for liver disease. Phlebotomy remains the mainstay of treatment and new treatments being studied include erythrocytapheresis and 'mini-hepcidins'. Iron overload is being recognized to play a carcinogenic role in hepatocellular carcinoma and other cancers, possibly supporting iron depletion in these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23985001     DOI: 10.1586/17474124.2013.816114

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  12 in total

Review 1.  Use of magnetic resonance imaging to monitor iron overload.

Authors:  John C Wood
Journal:  Hematol Oncol Clin North Am       Date:  2014-08       Impact factor: 3.722

Review 2.  Recent advances in hemochromatosis: a 2015 update : a summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia.

Authors:  Dilum Ekanayake; Clinton Roddick; Lawrie W Powell
Journal:  Hepatol Int       Date:  2015-03-12       Impact factor: 6.047

Review 3.  Hypoxia-inducible factors link iron homeostasis and erythropoiesis.

Authors:  Yatrik M Shah; Liwei Xie
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

Review 4.  Management of human factors engineering-associated hemochromatosis: A 2015 update.

Authors:  Menaka Sivakumar; Lawrie W Powell
Journal:  World J Hepatol       Date:  2016-03-18

Review 5.  The Role of Iron in Benign and Malignant Hematopoiesis.

Authors:  Sayantani Sinha; Joana Pereira-Reis; Amaliris Guerra; Stefano Rivella; Delfim Duarte
Journal:  Antioxid Redox Signal       Date:  2021-01-07       Impact factor: 7.468

6.  The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.

Authors:  Yang-Fan Lv; Xian Chang; Rui-Xi Hua; Guang-Ning Yan; Gang Meng; Xiao-Yu Liao; Xi Zhang; Qiao-Nan Guo
Journal:  J Cell Mol Med       Date:  2016-02-19       Impact factor: 5.310

Review 7.  Pathophysiological consequences and benefits of HFE mutations: 20 years of research.

Authors:  Ina Hollerer; André Bachmann; Martina U Muckenthaler
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

8.  Detection of Endogenous Iron Reduction during Hepatocarcinogenesis at Susceptibility-Weighted MR Imaging: Value for Characterization of Hepatocellular Carcinoma and Dysplastic Nodule in Cirrhotic Liver.

Authors:  Ruo-Kun Li; Suzanne L Palmer; Meng-Su Zeng; Jin-Wei Qiang; Frank Chen; Sheng-Xiang Rao; Ling-Li Chen; Yong-Ming Dai
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

9.  High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease.

Authors:  Janette Bester; Antoinette V Buys; Boguslaw Lipinski; Douglas B Kell; Etheresia Pretorius
Journal:  Front Aging Neurosci       Date:  2013-12-06       Impact factor: 5.750

10.  Autopsy relevance determining hemochromatosis: Case report.

Authors:  Sigitas Chmieliauskas; Dalius Banionis; Sigitas Laima; Gerda Andriuskeviciute; Sandra Mazeikiene; Jurgita Stasiuniene; Algimantas Jasulaitis; Sonata Jarmalaite
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.